All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer

 
• By Bridget Silverman
  
cancer cells
ODAC members considered PD-1 risk-benefit questions in two types of cancer. • Source: Shutterstock

More from US FDA Performance Tracker

More from US Advisory Committees